MedTrace Logo

An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

NCT01454531 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2015-03-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the tolerability of AVANZ.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

DRUG

AVANZ Phleum pratense

AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • JOAQUIN SASTRE, MD, PhD · FUNDACIÓN JIMÉNEZ DIAZ

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-03-31
Completion
2012-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01454531 on ClinicalTrials.gov